Uncategorized

Corvia Medical Releases Two-year Clinical Trial Results Confirming Sustained Benefit and Safety of Its Atrial Shunt in Heart Failure Patients

Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, announced two-year results from its REDUCE LAP-HF II randomized clinical trial confirming safety and sustained efficacy of the Corvia® Atrial Shunt in properly selected heart failure patients with preserved or mildly reduced ejection fraction.

Corvia Medical Releases Two-year Clinical Trial Results Confirming Sustained Benefit and Safety of Its Atrial Shunt in Heart Failure Patients Read More »

Thousand Oaks Biologics and GeneQuantum Healthcare Signed A Strategic Partnership Agreement for ADC Drug Development

Thousand Oaks Biologics Inc. and GeneQuantum Healthcare Co., Ltd. are pleased to announce that they have formed a strategic partnership focusing on the CMC development of ADC products with a core conjugation technology for more stable drug candidates.

Thousand Oaks Biologics and GeneQuantum Healthcare Signed A Strategic Partnership Agreement for ADC Drug Development Read More »

AlzeCure is Granted European Patent for NeuroRestore ACD856

AlzeCure Pharma AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer’s disease and pain, announced that the European Patent Office has granted a patent covering the company’s candidate drug ACD856, which is developed against Alzheimer’s disease and other disorders with cognitive impairment.

AlzeCure is Granted European Patent for NeuroRestore ACD856 Read More »

Scroll to Top